Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Summit shares fall as FDA rejects closely watched PD-1/VEGF drug

The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at biopharmadive.com →

More in Health & Medicine

More from Monday 16 November →